Copyright
©The Author(s) 2021.
World J Gastroenterol. Sep 28, 2021; 27(36): 6053-6063
Published online Sep 28, 2021. doi: 10.3748/wjg.v27.i36.6053
Published online Sep 28, 2021. doi: 10.3748/wjg.v27.i36.6053
Table 2 Antiviral drugs approved for children and adolescents with chronic hepatitis B virus infection[14]
Ages approved for drug administration | Drug dosage | Drug formulations | |
Interferon alfa-2b | ≥ 1 yr | 6 million UI/m2 three times a week | Subcutaneous injection |
Peginterferon alfa-2a | ≥ 3 yr | 180 µg/1.73 m2 once a week | Subcutaneous injection |
Lamivudine | ≥ 3 yr | 3 mg/kg daily (maximum 100 mg) | Oral solution (5 mg/mL) or tablets (100 mg) |
Entecavir | ≥ 2 yr | 10-30 kg: 0.015 mg/kg daily (maximum 0.5 mg) | Oral solution (0.05 mg/mL) or tablets (0.5 mg and 1 mg) |
> 30 kg: 0.5 mg daily | |||
Adefovir | ≥ 12 yr | 10 mg daily | Tablets (10 mg) |
Tenofovir disoproxil fumarate | ≥ 2 yr1 | 8 mg/kg daily (maximum 300 mg) | Oral powder (40 mg per 1 g) or tablets (150 mg, 200 mg, 250 mg and 300 mg) |
≥ 12 yr1 | 300 mg daily | ||
Tenofovir alafenamide | ≥ 12 yr2 | 25 mg daily | Tablet (25 mg) |
- Citation: Stinco M, Rubino C, Trapani S, Indolfi G. Treatment of hepatitis B virus infection in children and adolescents. World J Gastroenterol 2021; 27(36): 6053-6063
- URL: https://www.wjgnet.com/1007-9327/full/v27/i36/6053.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i36.6053